1. Home
  2. IOVA vs OUT Comparison

IOVA vs OUT Comparison

Compare IOVA & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • OUT
  • Stock Information
  • Founded
  • IOVA 2007
  • OUT 2013
  • Country
  • IOVA United States
  • OUT United States
  • Employees
  • IOVA N/A
  • OUT N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • OUT Real Estate Investment Trusts
  • Sector
  • IOVA Health Care
  • OUT Real Estate
  • Exchange
  • IOVA Nasdaq
  • OUT Nasdaq
  • Market Cap
  • IOVA 2.6B
  • OUT 2.9B
  • IPO Year
  • IOVA N/A
  • OUT N/A
  • Fundamental
  • Price
  • IOVA $5.91
  • OUT $18.94
  • Analyst Decision
  • IOVA Strong Buy
  • OUT Hold
  • Analyst Count
  • IOVA 9
  • OUT 6
  • Target Price
  • IOVA $23.33
  • OUT $19.00
  • AVG Volume (30 Days)
  • IOVA 9.1M
  • OUT 1.6M
  • Earning Date
  • IOVA 02-26-2025
  • OUT 02-19-2025
  • Dividend Yield
  • IOVA N/A
  • OUT 4.76%
  • EPS Growth
  • IOVA N/A
  • OUT N/A
  • EPS
  • IOVA N/A
  • OUT 1.41
  • Revenue
  • IOVA $90,858,000.00
  • OUT $1,838,900,000.00
  • Revenue This Year
  • IOVA $13,758.71
  • OUT N/A
  • Revenue Next Year
  • IOVA $171.20
  • OUT $1.95
  • P/E Ratio
  • IOVA N/A
  • OUT $13.40
  • Revenue Growth
  • IOVA 12751.20
  • OUT 1.37
  • 52 Week Low
  • IOVA $5.62
  • OUT $12.57
  • 52 Week High
  • IOVA $18.33
  • OUT $19.98
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 28.87
  • OUT 59.01
  • Support Level
  • IOVA $5.62
  • OUT $17.17
  • Resistance Level
  • IOVA $6.44
  • OUT $18.29
  • Average True Range (ATR)
  • IOVA 0.45
  • OUT 0.48
  • MACD
  • IOVA -0.10
  • OUT 0.08
  • Stochastic Oscillator
  • IOVA 11.46
  • OUT 83.48

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About OUT OUTFRONT Media Inc.

Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's major customers include entities within the retail, television, healthcare, and entertainment industries.

Share on Social Networks: